Identifying tobacco-genetic interactions through study of the aryl hydrocarbon receptor pathway.

通过研究芳基碳氢化合物受体途径来识别烟草与遗传的相互作用。

基本信息

  • 批准号:
    10372147
  • 负责人:
  • 金额:
    $ 66.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Human exposure to environmental toxins such as those in tobacco related products are the leading cause of preventable deaths in the United States, with the greatest effect on morbidity and mortality through promotion of coronary artery disease (CAD). However, the molecular mechanisms by which environmental exposures increase CAD risk are not well understood. Furthermore, genes that might participate in gene by environment interactions have been difficult to identify at the population level. Thus, our longterm goal is to use a reverse genetics approach to study the interaction of xenobiotic toxins with relevant known CAD-associated genes. One such gene is the aryl-hydrocarbon receptor (AHR). Well-known ligands of AHR are dioxins and poly-aryl hydrocarbons, which are major components of tobacco smoke and known promoters of atherosclerosis in animal models. Genes encoding AHR, its heterodimerization partner ARNT, and other factors in this pathway are all linked to CAD risk through human genetic association studies. Single cell RNA sequencing (scRNAseq) studies of smooth muscle cell (SMC)-specific Ahr knockout (KO) atherosclerotic mice showed a significant increase in the proportion of phenotypic transition SMC that express chondrocyte markers, identifying cells we term “chondromyocytes” (CMC). These findings were correlated with larger lesion size, increased lineage- traced SMC contribution to the plaque, decreased lineage-traced SMC in the fibrous cap, and increased lesion alkaline phosphatase activity in the Ahr KO mice. These findings reveal that Ahr expression in SMC inhibits their transition to CMC and ameliorates vascular disease pathophysiology. These data are in contrast with a number of studies showing that Ahr activation by xenobiotic ligands such as dioxin promote atherosclerosis, and suggest a unique hypothesis. We postulate that Ahr normally has a beneficial effect on SMC in the disease setting, inhibiting a harmful cell state transition to the CMC phenotype and disease progression, and that this protective effect is blocked by xenobiotic toxin activation. We thus propose to examine this hypothesis through the following Aims. In Aim 1, we will investigate how Ahr responds to xenobiotic ligand activation in the disease setting, with respect to SMC phenotype and cellular lesion anatomy. These studies will employ the Ahr SMC-specific conditional KO and SMC lineage traced ApoE KO atherosclerosis model. Aim 2 will focus on the transcriptomic and epigenomic effects of xenobiotic ligand in vivo activation with the same mouse disease model, with combined scRNAseq and single cell ATAC sequencing (scATACseq). Finally, in Aim 3 we propose to employ human coronary artery SMC as an in vitro model system to validate, and characterize the downstream pathways for, TFs identified in the previous Aim that interact with AHR to regulate the phenotypic transition of SMC to chondromyocytes. These studies investigate a highly innovative hypothesis, and will provide significant insights into cellular and molecular mechanisms by which tobacco and other environmental risk factors promote CAD risk.
人类接触环境毒素,如烟草相关产品中的毒素,是导致 美国可预防的死亡,通过推广对发病率和死亡率的影响最大 冠状动脉疾病(CAD)。然而,环境暴露的分子机制 增加冠心病风险还没有被很好地理解。此外,环境中可能参与基因的基因 在人口层面上,相互作用一直很难确定。因此,我们的长期目标是使用相反的方法 研究外源毒素与相关已知CAD相关基因相互作用的遗传学方法。 其中一个基因是芳香烃受体(AHR)。众所周知的AHR的配体是二恶英和多芳基 碳氢化合物是烟草烟雾的主要成分,也是已知的动脉粥样硬化的促进剂 动物模型。编码AHR、其异二聚化伙伴ARNT和该途径中的其他因子的基因 通过人类基因关联研究,都与冠心病风险有关。单细胞RNA测序(ScRNAseq) 对平滑肌细胞(SMC)特异的AhR基因敲除(KO)小鼠的研究表明, 表达软骨细胞标志物的表型转移型SMC比例增加,识别细胞 术语“软骨肌细胞”(CMC)。这些发现与更大的病变范围,更多的血统相关- 可追踪到SMC对斑块的贡献,纤维帽中血统可追溯的SMC减少,病变增加。 Ahr KO小鼠的碱性磷酸酶活力。这些发现表明AHR在SMC中的表达抑制 它们转变为CMC并改善血管疾病的病理生理学。这些数据与 大量研究表明,二恶英等异种配体激活AHR会促进动脉粥样硬化, 并提出了一个独特的假设。我们推测AHR在正常情况下对SMC有有益的影响 疾病背景,抑制有害细胞状态向CMC表型和疾病的转变 这种保护作用被外源毒素激活所阻断。因此,我们建议 通过以下目标来检验这一假设。在目标1中,我们将调查Ahr如何应对 异种生物配体在疾病背景下的激活,与SMC表型和细胞损伤解剖有关。 这些研究将使用Ahr SMC特定的条件性KO和SMC血统追踪的ApoE KO 动脉粥样硬化模型。目标2将集中于异种配体的转录和表观基因组效应。 联合使用scRNAseq和单细胞ATAC,用相同的小鼠疾病模型活体激活 测序(ScATACseq)。最后,在目标3中,我们建议使用人冠状动脉SMC作为体外培养的 用于验证和表征先前目标中确定的TF的下游路径的模型系统 它们与AHR相互作用,调节SMC向软骨肌细胞的表型转变。这些研究 研究一个高度创新的假说,并将提供对细胞和分子的重要见解 烟草和其他环境风险因素促进冠心病风险的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS QUERTERMOUS其他文献

THOMAS QUERTERMOUS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS QUERTERMOUS', 18)}}的其他基金

Molecular mechanisms of vascular calcification and their connection to coronary disease risk
血管钙化的分子机制及其与冠心病风险的关系
  • 批准号:
    10673742
  • 财政年份:
    2022
  • 资助金额:
    $ 66.76万
  • 项目类别:
Elucidating Genotype-Phenotype Relationship of Polygenic Dilated Cardiomyopathies: Administrative Supplement (INCLUDE)
阐明多基因扩张型心肌病的基因型-表型关系:行政补充(包括)
  • 批准号:
    10404723
  • 财政年份:
    2021
  • 资助金额:
    $ 66.76万
  • 项目类别:
Identifying tobacco-genetic interactions through study of the aryl hydrocarbon receptor pathway.
通过研究芳基碳氢化合物受体途径来识别烟草与遗传的相互作用。
  • 批准号:
    10207112
  • 财政年份:
    2021
  • 资助金额:
    $ 66.76万
  • 项目类别:
PDGFD regulates a transcriptional network to modulate smooth muscle cell transition and coronary artery disease risk
PDGFD 调节转录网络以调节平滑肌细胞转变和冠状动脉疾病风险
  • 批准号:
    10593934
  • 财政年份:
    2021
  • 资助金额:
    $ 66.76万
  • 项目类别:
Identifying tobacco-genetic interactions through study of the aryl hydrocarbon receptor pathway.
通过研究芳基碳氢化合物受体途径来识别烟草与遗传的相互作用。
  • 批准号:
    10591597
  • 财政年份:
    2021
  • 资助金额:
    $ 66.76万
  • 项目类别:
PDGFD regulates a transcriptional network to modulate smooth muscle cell transition and coronary artery disease risk
PDGFD 调节转录网络以调节平滑肌细胞转变和冠状动脉疾病风险
  • 批准号:
    10172666
  • 财政年份:
    2021
  • 资助金额:
    $ 66.76万
  • 项目类别:
PDGFD regulates a transcriptional network to modulate smooth muscle cell transition and coronary artery disease risk
PDGFD 调节转录网络以调节平滑肌细胞转变和冠状动脉疾病风险
  • 批准号:
    10385753
  • 财政年份:
    2021
  • 资助金额:
    $ 66.76万
  • 项目类别:
Single Cell Sequencing of Human iPSC-CM Subtype Identity and Function
人类 iPSC-CM 亚型身份和功能的单细胞测序
  • 批准号:
    9763916
  • 财政年份:
    2019
  • 资助金额:
    $ 66.76万
  • 项目类别:
LncRNA Transcriptional Mechanisms of Coronary Artery Disease Risk
冠状动脉疾病风险的 LncRNA 转录机制
  • 批准号:
    10327641
  • 财政年份:
    2019
  • 资助金额:
    $ 66.76万
  • 项目类别:
Genetic and Stem Cell Model of Cardiac Metabolic Disease
心脏代谢疾病的遗传和干细胞模型
  • 批准号:
    9893900
  • 财政年份:
    2019
  • 资助金额:
    $ 66.76万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.76万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了